Search Results

You are looking at 11 - 20 of 130 items for :

  • "febrile neutropenia" x
  • Refine by Access: All x
Clear All
Full access

Derek Weycker, Xiaoyan Li, Rich Barron, Hongsheng Wu, P.K. Morrow, Hairong Xu, Maureen Reiner, Jacob Garcia, Shivani K. Mhatre, and Gary H. Lyman

Background Neutropenia is a common side effect of myelosuppressive chemotherapy that increases the risk of infection, which is typically signaled by fever. When neutropenic patients develop fever (ie, febrile neutropenia [FN]), the likelihood

Full access

Sriman Swarup, Anita Sultan, Somedeb Ball, Francis Mogollon-Duffo, Nimesh Adhikari, Yin M. Myat, Myo H. Zaw, Catherine Jones, and Kyaw Z. Thein

) Conclusion: CDK 4/6 inhibitors–based regimen significantly contributed to all hematologic toxicities as well as febrile neutropenia. The improved efficacy outcomes and manageable toxicities with CDK 4/6 inhibitors are observed with proper supportive care and

Full access

Gary H. Lyman

Dr. Lyman has received research grant support from Amgen and GlaxoSmithKline and is on the speakers' bureau of Amgen and OrthoBiotech. References 1 Lyman GH Kuderer NM . Epidemiology of febrile neutropenia . Support Cancer Ther

Full access

Kimberly Rose Hedstrom, Margaret Rausa, Eric Gratias, and Stephen Hamilton

Background: The National Comprehensive Cancer Network (NCCN) establishes standard of care for patients receiving anticancer therapy, and classifies regimens based on febrile neutropenia (FN) and emesis risks. eviCore healthcare licenses NCCN

Full access

Gary H. Lyman and Jessica Malone Kleiner

– 454 . 2. Lyman GH Morrison VA Dale DC . Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy . Leuk Lymph 2003 ; 44 : 2069 – 2076 . 3. Lyman GH . Guidelines of

Full access

Pamala A. Pawloski, Cara L. McDermott, James H. Marshall, Vanita Pindolia, Catherine M. Lockhart, Catherine A. Panozzo, Jeffrey S. Brown, and Bernadette Eichelberger

Background Prophylaxis with the recombinant human granulocyte colony-stimulating factors (G-CSFs) filgrastim and pegfilgrastim prevents chemotherapy-induced neutropenia; reduces febrile neutropenia (FN) risk and infection-related and early

Full access

Weijia Wang, Edward Li, Kim Campbell, and Ali McBride

Introduction: Febrile neutropenia (FN) is a major dose-limiting toxicity of myelosuppressive chemotherapy that can result in hospitalization, dose reductions or treatment delays and compromised clinical outcomes. National Comprehensive Cancer

Full access

Jeffrey Crawford, Pamela Sue Becker, James O. Armitage, Douglas W. Blayney, Julio Chavez, Peter Curtin, Shira Dinner, Thomas Fynan, Ivana Gojo, Elizabeth A. Griffiths, Shannon Hough, Dwight D. Kloth, David J. Kuter, Gary H. Lyman, Mary Mably, Sudipto Mukherjee, Shiven Patel, Lia E. Perez, Adam Poust, Raajit Rampal, Vivek Roy, Hope S. Rugo, Ayman A. Saad, Lee S. Schwartzberg, Sepideh Shayani, Mahsa Talbott, Saroj Vadhan-Raj, Sumithira Vasu, Martha Wadleigh, Peter Westervelt, Jennifer L. Burns, and Lenora Pluchino

progress to febrile neutropenia (FN; ≥38.3°C orally or ≥38.0°C duration over 1 hour), which is a major dose-limiting toxicity of chemotherapy that often requires prolonged hospitalization and broad-spectrum antibiotic use. 1 Occurrences of severe

Full access

Jeffrey Crawford, James Armitage, Lodovico Balducci, Pamela Sue Becker, Douglas W. Blayney, Spero R. Cataland, Mark L. Heaney, Susan Hudock, Dwight D. Kloth, David J. Kuter, Gary H. Lyman, Brandon McMahon, Hope S. Rugo, Ayman A. Saad, Lee S. Schwartzberg, Sepideh Shayani, David P. Steensma, Mahsa Talbott, Saroj Vadhan-Raj, Peter Westervelt, Michael Westmoreland, Mary Dwyer, and Maria Ho

Neutropenia (<500 neutrophils/mcL or <1000 neutrophils/mcL and a predicted decline to ≤500/mcL over the next 48 h) and resulting febrile neutropenia (FN; ≥38.3°C orally or ≥38.0°C over 1 h) can be induced by myelosuppressive chemotherapy. FN, in turn, is a

Full access

Pamela Sue Becker, Elizabeth A. Griffiths, Laura M. Alwan, Kimo Bachiashvili, Anna Brown, Rita Cool, Peter Curtin, Shira Dinner, Ivana Gojo, Ashley Hicks, Avyakta Kallam, Wajih Zaheer Kidwai, Dwight D. Kloth, Eric H. Kraut, Daniel Landsburg, Gary H. Lyman, Ryan Miller, Sudipto Mukherjee, Shiven Patel, Lia E. Perez, Adam Poust, Raajit Rampal, Rachel Rosovsky, Vivek Roy, Hope S. Rugo, Sepideh Shayani, Sumithira Vasu, Martha Wadleigh, Kelly Westbrook, Peter Westervelt, Jennifer Burns, Jennifer Keller, and Lenora A. Pluchino

filgrastim and pegfilgrastim, are primarily used to reduce the incidence of febrile neutropenia (FN) in patients with nonmyeloid malignancies receiving myelosuppressive chemotherapy. FN is a major dose-limiting toxicity of many chemotherapy regimens. Patients